摘要
重度抑郁症(MDD)是一种多因素的异质性疾病。充分的证据表明炎症反应参与了抑郁症的发病机制的一个亚群个体。然而,在患有抑郁症的群体中,关于炎症发作前是的特征和/或状态目前还不清楚。最近几项研究表明,一氧化氮(NO)为对神经炎症一种重要的调节因子,从而表明在抑郁症的病理生理学作用。本综述的目的是评估此证据基础支持的假说,即在一些特定的人群中抑郁症风险的增加是可以介导的。在某种程度上,通过炎症基因特质和/或没有信号通路的状态变化。从1985到2014年10月,我们通过PubMed和Google Scholar进行了关于英语语言研究的一项非系统的文献调查。复制的证据表明,NO对中枢神经系统有对比性的效果(CNS)。低浓度的NO有神经保护作用并介导生理信号, 而高浓度的NO介导神经炎症作用并具有神经毒性。某些在神经元型一氧化氮合成酶的基因多态性(NOS1)与抑郁症相关。此外,状态的变化(如减少必要的辅助因子的水平,5,6,7,8-tetrahydrobiopterin[BH4],小胶质细胞活性增强)在没有信号通路与患抑郁症的风险增加有关。增加NO的浓度提高活性氮的产生(RNS)并激活活性氧簇(ROS),这与促炎性细胞因子的增加有关。综合考虑,证据表明在NO信号传输的异常可能构成抑郁症的病理生理相关性状的分子标记,这可能探索新的治疗靶点。
关键词: 抑郁症,一氧化氮,炎症,氧化应激,一氧化氮合酶,内表型,综述。
Current Molecular Medicine
Title:Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications
Volume: 16 Issue: 2
Author(s): P. Kudlow, D.S. Cha, A.F. Carvalho and R.S. McIntyre
Affiliation:
关键词: 抑郁症,一氧化氮,炎症,氧化应激,一氧化氮合酶,内表型,综述。
摘要: Major depressive disorder (MDD) is a multi-factorial and heterogeneous disease. Robust evidence suggests that inflammation is involved in the pathogenesis of MDD for a subpopulation of individuals. However, it remains unclear what traits and/or states precede the onset of inflammation in this subpopulation of individuals with MDD. Several recent studies have implicated nitric oxide (NO) as a critical regulator of neuroinflammation, thus suggesting a possible role in the pathophysiology of MDD. The aim of this review is to evaluate the evidentiary base supporting the hypothesis that the increased hazard for developing MDD in certain subpopulations may be mediated, in part, by inflammogenic trait and/or state variations in NO signaling pathways. We conducted a non-systematic literature search for English language studies via PubMed and Google Scholar, from 1985 to October 2014. Replicated evidence suggests that NO has contrasting effects in the central nervous system (CNS). Low concentrations of NO are neuroprotective and mediate physiological signaling whereas higher concentrations mediate neuroinflammatory actions and are neurotoxic. Certain polymorphisms in the neuronal nitric oxide synthase gene (NOS1) are associated MDD. Furthermore, state variations (e.g. decreased levels of essential co-factor, 5,6,7,8-tetrahydrobiopterin [BH4], enhanced microglial cell activity) in the NO signaling pathway are associated with an increased risk of developing MDD. Increased concentrations of NO enhance the production of reactive nitrogen species (RNS) and reactive oxygen species (ROS), which are associated with an increase in pro-inflammatory cytokines. Taken together, evidences suggest that abnormalities in NO signaling may constitute a trait-marker related to MDD pathophysiology, which could be explored for novel therapeutic targets.
Export Options
About this article
Cite this article as:
P. Kudlow, D.S. Cha, A.F. Carvalho and R.S. McIntyre , Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications, Current Molecular Medicine 2016; 16 (2) . https://dx.doi.org/10.2174/1566524016666160126144722
DOI https://dx.doi.org/10.2174/1566524016666160126144722 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effect of Local Alcohol Delivery in Reducing Intimal Hyperplasia Induced by Vascular Injury and the Clinical Implications
Vascular Disease Prevention (Discontinued) Advances in Irrigated Tip Catheter Technology for Treatment of Cardiac Arrhythmias
Recent Patents on Cardiovascular Drug Discovery Novel Approaches in the Treatment of Antipsychotic-Induced Hyperprolactinemia: The Role of Partial Agonists of D2 Dopaminergic Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Bile Acid Reabsorption Inhibitors (BARI): Novel Hypolipidemic Drugs
Current Medicinal Chemistry Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Your Father and Grandfather’s Atrial Fibrillation: A Review of the Genetics of the Most Common Pathologic Cardiac Dysrhythmia
Current Genomics Piperine: Medicinal, Analytical and Therapeutics perspective
Current Bioactive Compounds Measurements of Thermodynamic Acid Dissociation Constants for Three HMG-CoA Reductase Inhibitors by using RPLC and Study of Validation in Pharmaceutical Tablets
Current Pharmaceutical Analysis Editorial (Thematic Issue: Antithrombotic Therapy: Current and Future Clinical Use)
Current Vascular Pharmacology Drug-Like Inhibitors of Protein-Protein Interactions: A Structural Examination of Effective Protein Mimicry
Current Protein & Peptide Science Cytochrome P450 Drug Metabolizing Enzymes in Roma Population Samples: Systematic Review of the Literature
Current Medicinal Chemistry Hypoxia and Fetal Heart Development
Current Molecular Medicine Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Therapeutic Option of Plasmid-DNA Based Gene Transfer
Current Topics in Medicinal Chemistry Regulation of Endothelial Nitric Oxide Synthase in Pathophysiological Conditions
Cardiovascular & Hematological Disorders-Drug Targets Rational Basis for Nutraceuticals in the Treatment of Glaucoma
Current Neuropharmacology The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology